About Immutrix Therapeutics
Immutrix Therapeutics is a private company based in Rapid City, South Dakota. It has reported $14,497,350 raised in six offerings on Form D since June 2016. Its chief executive is Ronald Shape.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 18, 2025 | Sep 22, 2025 | $480,000of $5.0M target | 1 | $480K | DebtRule 506(b) | Form D ↗ |
| Jul 1, 2020 | Jul 14, 2020 | $300,000of $15.0M target | 1 | $300K | EquityRule 506(b) | Form D ↗ |
| Aug 31, 2019 | Sep 5, 2019 | $450,000of $2.0M target | 2 | $225K | Debt, Securities on exercise, Convertible NotesRule 506(b) | Form D ↗ |
| Nov 13, 2017 | Nov 27, 2017amended Oct 12, 2018 | $5,277,500of $16.0M target | 26 | $202K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Jun 4, 2014 | Jun 28, 2016amended Jul 22, 2016 | $4,089,850of $5.0M target | 34 | $120K | Equity, Common StockRule 506(b) | Form D/A ↗1 earlier filing |
| Oct 16, 2015 | Oct 20, 2015 | $3,900,000of $6.5M target | 1 | $3.9M | EquityRule 506(b) | Form D ↗ |
| Total, six offerings | $14,497,350 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Immutrix Therapeutics's Form D filed Sep 22, 2025.
DS
Dan Smith
Chief Operating Officer
BH
Brad Hennrich
Director
RO
Rich Otto
Director
CR
Carol Rae
Director
LB
Lonnie Bookbinder
Director
RS
Ronald Shape
President, CEO and CFO, director
SU
Stephanie D'Urso
Director
RM
Russell McCulloh
Director
Earlier filings also listed Roy Ketel (cfo and director, last listed Jul 2020), Craig Hansen (director, last listed Jul 2020), Brent Phillips (director, last listed Jul 2020), Leroy Ketel (cfo, secretary and director, last listed Sep 2019) and James Scull (director, last listed Sep 2019).